ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

NVCR NovoCure Ltd

13,40
0,66 (5,18%)
Vor Marktöffnung
Zuletzt aktualisiert: 14:13:42
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
NovoCure Ltd NVCR NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,66 5,18% 13,40 14:13:42
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
12,74
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
02.5.202413:01BWNovocure Secures New $400 Million Multi-Tranche Non-Dilutive..
02.5.202413:00BWNovocure Reports First Quarter 2024 Financial Results
24.4.202416:45BWResults of Novocure’s METIS Phase 3 Clinical Trial for..
05.4.202413:00BWNovocure Announces 20 Presentations On Tumor Treating..
01.4.202413:00BWNovocure to Report First Quarter 2024 Financial Results
29.3.202401:07BWMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
28.3.202418:51BWKlinische Phase-3-Studie METIS erreicht primären Endpunkt..
28.3.202418:50BWL’essai clinique de phase 3 METIS a atteint son critère..
27.3.202412:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint,..
11.3.202412:00BWINNOVATE-3 Late Breaking Abstract Selected as a Best Oral..
05.3.202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.3.202400:39EDGAR2Form 144 - Report of proposed sale of securities
04.3.202423:56EDGAR2Form 144 - Report of proposed sale of securities
01.3.202423:06EDGAR2Form 144 - Report of proposed sale of securities
01.3.202423:01EDGAR2Form 144 - Report of proposed sale of securities
29.2.202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.2.202413:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22.2.202413:06EDGAR2Form 8-K - Current report
22.2.202413:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22.2.202413:00BWNovocure Reports Fourth Quarter and Full Year 2023 Financial..
18.1.202417:10DJNNovocure Shares Rise 17% After FDA Accepts Pre-Market..
18.1.202413:01EDGAR2Form 8-K - Current report
18.1.202413:00BWNovocure Announces FDA Acceptance of the PMA Application for..
12.1.202422:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
09.1.202413:00EDGAR2Form 8-K - Current report
09.1.202413:00BWNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT..
08.1.202413:10EDGAR2Form 8-K - Current report
08.1.202413:00BWNovocure Announces Preliminary Full Year and Fourth Quarter..
04.1.202422:10EDGAR2Form 8-K - Current report
04.1.202422:05BWNovocure Appoints Dr. Nicolas Leupin as Chief Medical..
27.12.202313:00BWNovocure to Participate in 42nd Annual J.P. Morgan..
28.11.202313:30EDGAR2Form 8-K - Current report
28.11.202313:30BWNovocure Announces Portfolio Prioritization and Strategic..
21.11.202313:00BWNovocure to Participate in 35th Annual Piper Sandler..
10.11.202314:00BWNovocure Announces Presentations on Tumor Treating Fields..
08.11.202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.11.202321:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.11.202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.10.202313:03EDGAR2Form 8-K - Current report
26.10.202313:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
26.10.202313:00BWNovocure Reports Third Quarter 2023 Financial Results
16.10.202300:05BWNovocure Announces Presence at European Society for Medical..
12.10.202314:00BWNovocure and Stanford School of Medicine to Establish Tumor..
02.10.202313:00BWNovocure to Report Third Quarter 2023 Financial Results
29.9.202323:00BWNovocure Announces Presence at American Society for..
08.9.202322:01BWNovocure Highlights Use of Tumor Treating Fields Therapy in..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock